Citations

Clear

1446 citation(s) found for "Howard, F".

Prevalence of Antibody to Chlamydia in Renal Transplant Recipients and Other Population Groups
Smith, Thomas F., Vanscoy, Robert E., Taswell, Howard F., Wilson, Daniel J.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 129 | Issue: 2 | Pages: 441-441

10.1016/s0022-5347(17)52139-4 Get It

Congenital Ureteral Valves: Report of two Cases
Simon, Howard B., Culp, Ormond S., Parkhill, Edith M.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 74 | Issue: 3 | Pages: 336-341

10.1016/s0022-5347(17)67286-0 | PMID 13252710 Get It

Argentaffin Tumor (Carcinoid) Occurring in a Benign Cystic Teratoma of the Testicle
Simon, Howard B., McDonald, John R., Culp, Ormond S.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 72 | Issue: 5 | Pages: 892-894

10.1016/s0022-5347(17)67688-2 | PMID 13212896 Get It

SUPPORT TO AGING PARENTS: IMPLICATIONS FOR MIDDLE-AGED CHILDREN’S DIURNAL CORTISOL AND DAILY MOOD
Bangerter, Lauren R. , Liu, Y. , Fingerman, Karen L. , Liu, Y., Zarit, Steven Howard , Birditt, Kira S.

Mayo Clinic

Innovation in Aging | June 30, 2017 | Volume: 1 | Issue: suppl_1 | Pages: 12-12

10.1093/geroni/igx004.041 Get It

Transurethral Resection in Infants and Children for Congenital Obstruction of the Vesical Neck and Myelodysplasia
Emmett, John L., Simon, Howard B.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 76 | Issue: 5 | Pages: 595-608

10.1016/s0022-5347(17)66739-9 | PMID 13377471 Get It

Rare Type of Prostatic Hyperplasia with Unusual Clinical Observations: Report of a Case
Thompson, Gershom J., Hammer, Howard J.

Mayo Clinic

Journal of Urology | June 29, 2017 | Volume: 42 | Issue: 1 | Pages: 47-49

10.1016/s0022-5347(17)71483-8 Get It

Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.
Basch, Ethan , Deal, Allison M. , Atkinson, Thomas M. , Scher, Howard I. , Hudis, Clifford A. , Sabbatini, Paul , Rogak, Lauren J. , Leahy, Allison Barz , Basch, Ethan , Deal, Allison , Dueck, Amylou C. , Bennett, Antonia V , Kris, Mark G. , Dulko, Dorothy , Schrag, Deborah , Leahy, Allison B

Mayo Clinic

Journal of Clinical Oncology | June 13, 2017 | Volume: 35 | Issue: 18_suppl | Pages: LBA2-LBA2

10.1200/jco.2017.35.18_suppl.lba2 Get It

LBA2 Background: We previously reported significant benefits in quality of life, patient satisfaction, and emergency room utilization outcomes from a large single-center randomized controlled trial comparing web-based symptom monitoring with patient-reported outcomes (PROs) vs. usual care in patients receiving chemotherapy for metastatic solid tumors (Clinicaltrials.gov: NCT00578006). We now present overall survival results from this trial. Methods: Patients receiving routine outpatient chemotherapy for metastatic solid tumors at Memorial Sloan Kettering Cancer Center were randomly assigned to self-report 12 common symptoms via tablet computers (“PRO intervention”), or to usual care. Treating physicians received symptom printouts at visits and nurses received email alerts when participants reported severe or worsening symptoms. Overall survival was tabulated based on medical records and Social Security Death Index data, estimated using the Kaplan-Meier method, and compared between arms using a log-rank test and Cox proportional hazards regression adjusting for age, sex, race, education level, and cancer type. Results: Between September 2007 and January 2011, 766 patients were randomized, with median age 61 (range 26-91), 86% white, 58% female, and 22% with less than high school education. Cancer types included genitourinary (32% of patients), gynecologic (23%), breast (19%), and lung cancer (26%). Survival results were assessed in June 2016 after a median follow up of 7 years and 517/766 (67%) of participants had died. Median overall survival in the PRO intervention arm was 5 months longer than the control arm (31.2 vs. 26.0 months, p = 0.03). In the multivariable model, results remained statistically significant with a hazard ratio of 0.832 (p = 0.04; 95% CI; 0.696, 0.995). Conclusions: Systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes confers overall survival benefits. These single-center results are being further evaluated in a national multicenter implementation trial. Clinical trial information: NCT00578006.
CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST‐LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE.
Fornecker, Luc-Mathieu, Sebban, Catherine, Marcus, R. E., Höchster, Howard S. , Rummel, Mathias , Hagenbeeck, A., Herold, Michael , Nielsen, Tina, Foon, K., Flowers, Christopher R. , Shi, Q., Ou, Fang‐Shu , Dixon, Jesse G. , Casulo, Carla , Hoster, Eva , Klapper, Wolfram , Morschhauser, Franck , Kimby, Eva , Peterson, B.A., Gyan, Emmanuel , Ladetto, Marco , Zucca, Emanuele , Vitolo, Umberto , Shi, Q., Salles, Gilles

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 225-226

10.1002/hon.2438_89 Get It

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Basch, Ethan , Deal, Allison M. , Dueck, Amylou C. , Scher, Howard I. , Hudis, Clifford A. , Dueck, A. C. , Basch, Ethan , Deal, Allison , Kris, Mark G. , Schrag, Deborah

Mayo Clinic

JAMA | June 6, 2017 | Volume: 318 | Issue: 2 | Pages: 197

10.1001/jama.2017.7156 | PMID 28586821 Get It